Patents by Inventor David A. Cory

David A. Cory has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TREATMENT OF HEPATITIS DELTA VIRUS INFECTION
    Publication number: 20250387377
    Abstract: Methods of reducing hepatitis delta virus (HDV) viral loads in a patient are provided. In some embodiments, the method comprises treating the patient with lonafarnib-ritonavir co-therapy. In some embodiments, the method further comprises treating the patient with an interferon.
    Type: Application
    Filed: January 17, 2025
    Publication date: December 25, 2025
    Applicant: EIT Pharma, Inc.
    Inventors: David A. Cory, Ingrid Choong, Jeffrey S. Glenn
  • Treatment of hepatitis delta virus infection
    Patent number: 12290509
    Abstract: Methods of reducing hepatitis delta virus (HDV) viral loads in a patient are provided. In some embodiments, the method comprises treating the patient with lonafarnib-ritonavir co-therapy. In some embodiments, the method further comprises treating the patient with an interferon.
    Type: Grant
    Filed: September 15, 2023
    Date of Patent: May 6, 2025
    Assignee: EIT Pharma, Inc.
    Inventors: David A. Cory, Ingrid Choong, Jeffrey S. Glenn
  • TREATMENT OF HEPATITIS DELTA VIRUS INFECTION
    Publication number: 20240277676
    Abstract: Methods of reducing hepatitis delta virus (HDV) viral loads in a patient are provided. In some embodiments, the method comprises treating the patient with lonafarnib-ritonavir co-therapy. In some embodiments, the method further comprises treating the patient with an interferon.
    Type: Application
    Filed: September 15, 2023
    Publication date: August 22, 2024
    Applicant: Eiger Biopharmaceuticals, Inc.
    Inventors: David A. Cory, Ingrid Choong, Jeffrey S. Glenn
  • Treatment of hepatitis delta virus infection
    Patent number: 11793793
    Abstract: Methods of reducing hepatitis delta virus (HDV) viral loads in a patient are provided. In some embodiments, the method comprises treating the patient with lonafarnib-ritonavir co-therapy. In some embodiments, the method further comprises treating the patient with an interferon.
    Type: Grant
    Filed: March 18, 2022
    Date of Patent: October 24, 2023
    Assignee: Eiger Biopharmaceuticals, Inc.
    Inventors: David A. Cory, Ingrid Choong, Jeffrey S. Glenn
  • TREATMENT OF HEPATITIS DELTA VIRUS INFECTION
    Publication number: 20230046607
    Abstract: Methods of reducing hepatitis delta virus (HDV) viral loads in a patient are provided. In some embodiments, the method comprises treating the patient with lonafarnib-ritonavir co-therapy. In some embodiments, the method further comprises treating the patient with an interferon.
    Type: Application
    Filed: March 18, 2022
    Publication date: February 16, 2023
    Inventors: David A. Cory, Ingrid Choong, Jeffrey S. Glenn
  • Methods for the treatment of non-alcoholic steatohepatitis
    Patent number: 11571403
    Abstract: In one aspect, methods of treating non-alcoholic steatohepatitis (NASH) or preventing or delaying the progression of non-alcoholic fatty liver disease (NAFLD) to NASH are provided. In some embodiments, the method comprises administering a therapeutically effective amount of ubenimex.
    Type: Grant
    Filed: February 4, 2020
    Date of Patent: February 7, 2023
    Assignee: Eiger BioPharmaceuticals, Inc.
    Inventors: Xiaofeng Xiong, David A. Cory
  • Treatment of hepatitis delta virus infection
    Patent number: 11311519
    Abstract: Methods of reducing hepatitis delta virus (HDV) viral loads in a patient are provided. In some embodiments, the method comprises treating the patient with lonafarnib-ritonavir co-therapy. In some embodiments, the method further comprises treating the patient with an interferon.
    Type: Grant
    Filed: August 18, 2020
    Date of Patent: April 26, 2022
    Assignee: Eiger BioPharmaceuticals, Inc.
    Inventors: David A. Cory, Ingrid Choong, Jeffrey S. Glenn
  • TREATMENT OF HEPATITIS DELTA VIRUS INFECTION
    Publication number: 20200375955
    Abstract: Methods of reducing hepatitis delta virus (HDV) viral loads in a patient are provided. In some embodiments, the method comprises treating the patient with lonafarnib-ritonavir co-therapy. In some embodiments, the method further comprises treating the patient with an interferon.
    Type: Application
    Filed: August 18, 2020
    Publication date: December 3, 2020
    Inventors: David A. Cory, Ingrid Choong, Jeffrey S. Glenn
  • Treatment of hepatitis delta virus infection
    Patent number: 10828283
    Abstract: Methods of reducing hepatitis delta virus (HDV) viral loads in a patient are provided. In some embodiments, the method comprises treating the patient with lonafarnib-ritonavir co-therapy. In some embodiments, the method further comprises treating the patient with an interferon.
    Type: Grant
    Filed: August 1, 2018
    Date of Patent: November 10, 2020
    Assignee: Eiger Biopharmaceuticals, Inc.
    Inventors: David A. Cory, Ingrid Choong, Jeffrey S. Glenn
  • METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS
    Publication number: 20200237696
    Abstract: In one aspect, methods of treating non-alcoholic steatohepatitis (NASH) or preventing or delaying the progression of non-alcoholic fatty liver disease (NAFLD) to NASH are provided. In some embodiments, the method comprises administering a therapeutically effective amount of ubenimex.
    Type: Application
    Filed: February 4, 2020
    Publication date: July 30, 2020
    Inventors: Xiaofeng Xiong, David A. Cory
  • Methods and pharmaceutical compositions for the treatment of non-alcoholic steatohepatitis
    Patent number: 10588880
    Abstract: In one aspect, methods of treating non-alcoholic steatohepatitis (NASH) or preventing or delaying the progression of non-alcoholic fatty liver disease (NAFLD) to NASH are provided. In some embodiments, the method comprises administering a therapeutically effective amount of ubenimex.
    Type: Grant
    Filed: September 28, 2017
    Date of Patent: March 17, 2020
    Assignee: Eiger BioPharmaceuticals, Inc.
    Inventors: Xiaofeng Xiong, David A. Cory
  • METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS
    Publication number: 20190307714
    Abstract: In one aspect, methods of treating non-alcoholic steatohepatitis (NASH) or preventing or delaying the progression of non-alcoholic fatty liver disease (NAFLD) to NASH are provided. In some embodiments, the method comprises administering a therapeutically effective amount of ubenimex.
    Type: Application
    Filed: September 28, 2017
    Publication date: October 10, 2019
    Inventors: Xiaofeng Xiong, David A. Cory
  • TREATMENT OF HEPATITIS DELTA VIRUS INFECTION
    Publication number: 20190167646
    Abstract: Methods of reducing hepatitis delta virus (HDV) viral loads in a patient are provided. In some embodiments, the method comprises treating the patient with lonafarnib-ritonavir co-therapy. In some embodiments, the method further comprises treating the patient with an interferon.
    Type: Application
    Filed: August 1, 2018
    Publication date: June 6, 2019
    Applicant: Eiger BioPharmaceuticals, Inc.
    Inventors: David A. Cory, Ingrid Choong, Jeffrey S. Glenn
  • Treatment of hepatitis delta virus infection
    Patent number: 10076512
    Abstract: Methods of reducing hepatitis delta virus (HDV) viral loads in a patient are provided. In some embodiments, the method comprises treating the patient with lonafarnib-ritonavir co-therapy. In some embodiments, the method further comprises treating the patient with an interferon.
    Type: Grant
    Filed: October 26, 2016
    Date of Patent: September 18, 2018
    Assignee: Eiger BioPharmaceuticals, Inc.
    Inventors: David A. Cory, Ingrid Choong, Jeffrey S. Glenn
  • TREATMENT OF HEPATITIS DELTA VIRUS INFECTION
    Publication number: 20170042862
    Abstract: Methods of reducing hepatitis delta virus (HDV) viral loads in a patient are provided. In some embodiments, the method comprises treating the patient with lonafarnib-ritonavir co-therapy. In some embodiments, the method further comprises treating the patient with an interferon.
    Type: Application
    Filed: October 26, 2016
    Publication date: February 16, 2017
    Applicant: Eiger BioPharmaceuticals, Inc.
    Inventors: David A. Cory, Ingrid Choong, Jeffrey S. Glenn